brand

Syngenta Paraquat Lawsuit

Preparing your case review…
Written By
People's Justice Legal Research Team

Syngenta: Corporate History and Liability

Syngenta AG is the world’s largest paraquat manufacturer and the primary defendant in MDL 3004. Understanding Syngenta’s corporate history is essential to understanding the litigation, because the company inherited both the product and the decades of suppressed knowledge about its dangers from its corporate predecessors.

Imperial Chemical Industries (ICI), the British chemical conglomerate, developed and commercialized paraquat beginning in the early 1960s. ICI’s internal research identified neurotoxic properties of the compound as early as 1958 — before commercial marketing began. In 1966, ICI researchers confirmed that paraquat enters the brain in mice. Throughout the following decades, ICI conducted additional internal studies documenting neurological effects, including the Louise Marks studies in the 1990s that showed cell loss in the substantia nigra of paraquat-exposed animals. These results were suppressed and not reported to regulators.

ICI’s agrochemical division was spun off as Zeneca in 1993. Zeneca merged with Novartis’s crop science division in 2000 to form Syngenta, which inherited the paraquat product line and all associated liabilities — including the accumulated knowledge of neurotoxicity. In 2003, Syngenta developed its "Scientific Influencing Strategy," a coordinated program to selectively fund and publish favorable research while suppressing and discrediting independent scientists whose work linked paraquat to Parkinson’s disease.

ChemChina Acquisition and Ongoing Liability

In 2017, China National Chemical Corporation (ChemChina) acquired Syngenta for $43 billion — the largest-ever Chinese acquisition of a foreign company. The acquisition transferred all of Syngenta’s paraquat liabilities to the Chinese state-owned entity. Ironically, China itself banned paraquat in 2017, creating the remarkable situation of a Chinese government entity owning the world’s largest manufacturer of a product that China had banned within its own borders.

Despite the ownership change, Syngenta continues to manufacture and sell paraquat in markets where it remains legal, including the United States. The company faces approximately 5,000 pending cases in MDL 3004, has paid $187.5 million in initial settlements, and agreed to a broader framework settlement in April 2025. The litigation’s trajectory suggests that Syngenta’s total paraquat liability will be measured in billions of dollars before the MDL is fully resolved.

Research & Evidence

Scientific Evidence

cross-sectional

Paraquat and Parkinson’s Disease: The Role of Corporate Agnotology

Dorsey ER, et al. (2023). Movement Disorders

Key Findings

  • Syngenta’s corporate predecessor ICI identified paraquat neurotoxicity in 1958 and confirmed brain penetration in 1966
  • The Louise Marks studies documenting substantia nigra cell loss in paraquat-exposed animals were suppressed and not reported to regulators
  • Syngenta’s 2003 "Scientific Influencing Strategy" was a coordinated effort to selectively publish favorable research while discrediting independent scientists
  • Syngenta specifically targeted Dr. Deborah Cory-Slechta and hired v-Fluence to manage reputation and influence scientific discourse
  • The pattern mirrors tobacco industry agnotology documented by Proctor and others, representing a deliberate corporate strategy to maintain a profitable product at the expense of public health
meta-analysis

Exposure to Pesticides or Solvents and Risk of Parkinson Disease (Meta-Analysis)

Pezzoli G, Cereda E. (2013). Neurology

Key Findings

  • Paraquat exposure was associated with an overall odds ratio of 1.64 for Parkinson’s disease, confirming a statistically significant increased risk
  • The association was consistent across multiple independent studies conducted in different countries and populations
  • Herbicide and pesticide exposure in general was associated with a pooled odds ratio of 1.62 for Parkinson’s disease
  • The meta-analytic approach provides the aggregated statistical power that individual studies cannot achieve, strengthening the causal inference
cohort

Rotenone, Paraquat, and Parkinson’s Disease (FAME Study)

Tanner CM, Kamel F, Ross GW, et al. (2011). Environmental Health Perspectives

Key Findings

  • Paraquat users had a 2.5-fold (250%) increased risk of Parkinson’s disease compared to non-users
  • The association was statistically significant and persisted after controlling for confounding variables including age, sex, smoking, and other pesticide exposures
  • Rotenone use was also associated with increased Parkinson’s risk (2.5x), and both compounds inhibit mitochondrial complex I through similar mechanisms
  • The study used objective pesticide application records rather than self-reported exposure, substantially reducing recall bias
FAQ

Frequently Asked Questions

See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
Related Topics

Related Pages

Paraquat Aerial Spray Drift

Aerial application of paraquat produces spray drift that can carry the herbicide hundreds of meters or more from the target area, exposing rural residents, schoolchildren, and bystanders who never directly handled the chemical. Drift exposure is a recognized pathway in the paraquat litigation, and individuals who lived near aerial paraquat operations and developed Parkinson’s disease may have viable claims.

spray-driftaerial-applicationcrop-dusting
Learn more

Paraquat & Early-Onset Parkinson’s

Early-onset Parkinson’s disease (diagnosed before age 50) is more strongly associated with environmental exposures like paraquat than late-onset cases. Individuals who developed Parkinson’s at a younger age after paraquat exposure may have particularly strong claims because early onset is a marker of environmental causation rather than normal aging.

early-onsetyoung-onsetparkinsons
Learn more

Paraquat EPA Ban

Despite more than 70 countries banning paraquat and overwhelming scientific evidence linking it to Parkinson’s disease, the U.S. Environmental Protection Agency has repeatedly declined to ban the herbicide. The EPA’s 2024 registration review reaffirmed paraquat’s approval despite 90 studies submitted by the Michael J. Fox Foundation. This regulatory failure is cited in the litigation as evidence that judicial remedies are necessary to protect American farmworkers and rural communities.

epabanregulation
Learn more

Paraquat Farmworker Exposure

Agricultural workers and farmworkers bear the heaviest burden of paraquat exposure. An estimated 10 million pounds of paraquat are applied annually in the United States, and farmworkers — the majority of whom are Latino — face direct exposure through field work, crop handling, and inadequate protective equipment. The paraquat litigation seeks compensation for farmworkers who developed Parkinson’s disease as a result of occupational exposure.

farmworkeragricultural-workeroccupational-exposure
Learn more

Paraquat Parkinson’s Disease Lawsuit

Paraquat exposure causes Parkinson’s disease through a well-characterized mechanism of oxidative stress, mitochondrial dysfunction, and selective dopaminergic neuron death. The FAME study found a 2.5x increased risk, and MDL 3004 encompasses approximately 5,000 cases seeking compensation for individuals diagnosed with Parkinson’s after paraquat exposure.

parkinsonslawsuitparaquat
Learn more

Paraquat Settlement Amounts

Paraquat Parkinson’s settlement amounts are projected to range from $20,000 for early-stage cases to over $1,000,000 for severe, long-duration cases with strong exposure documentation. The MDL framework settlement agreement reached in April 2025 provides the structure for individual case resolution. Average projected settlements are $600,000 to $900,000. Filing now positions your claim for the current settlement distribution cycle.

settlementcompensationdamages
Learn more

Paraquat Wrongful Death Claims

Surviving family members can file wrongful death claims on behalf of loved ones who died from Parkinson’s disease caused by paraquat exposure. Parkinson’s is a progressive and ultimately fatal disease, and many paraquat-exposed individuals have already passed away. Wrongful death claims seek compensation for medical costs before death, funeral expenses, lost financial support, and loss of companionship.

wrongful-deathsurvival-actionfamily-claims
Learn more
Parent Case

Paraquat Parkinson’s Lawsuit

Paraquat is a restricted-use herbicide manufactured primarily by Syngenta and distributed by Chevron Phillips Chemical and Growmark. Despite being banned in more than 70 countries including the European Union, China, Brazil, and Thailand, paraquat remains legal in the United States, where approximately 10 million pounds are applied annually. Scientific evidence — including the landmark Farming and Movement Evaluation (FAME) study published in 2011 — demonstrates that paraquat exposure increases the risk of Parkinson’s disease by 2.5 times. The mechanism is well understood: paraquat triggers oxidative stress through redox cycling, inhibits mitochondrial complex I, and selectively kills dopamine-producing neurons in the substantia nigra, leading to the progressive motor and cognitive deterioration characteristic of Parkinson’s disease. MDL 3004 was established in June 2021 in the Southern District of Illinois, with approximately 5,000 cases pending. Bellwether proceedings and settlement negotiations are ongoing, with projected individual settlements ranging from $20,000 to over $1,000,000 depending on disease severity and exposure documentation.

View full case overview